Clinical Trials Logo

Prostatic Hyperplasia clinical trials

View clinical trials related to Prostatic Hyperplasia.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06466369 Active, not recruiting - Clinical trials for BPH With Other Lower Urinary Tract Symptoms

Administration of Tadalafil in Patients With Benign Prostatic Hyperplasia

Start date: March 15, 2024
Phase: Phase 3
Study type: Interventional

The aim of the present study is to evaluate the efficacy and safety of once daily administration PDE5 inhibitors, tadalafil for 3 months as anti-inflammatory, antiproliferative and relaxant effects in ED with BPH patients.

NCT ID: NCT06051383 Active, not recruiting - Clinical trials for Benign Prostatic Hyperplasia

Outcome of Conducting Self-management Intervention on Severity of Lower Urinary Tract Symptoms

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

Aim of this study is to evaluate the effect of conducting self-management interventions on severity of lower urinary tract symptoms (LUTS) for patients with benign prostatic hyperplasia (BPH). Research hypothesis: To fulfill the aim of this study, the following research hypothesis was formulated: Patients with benign prostatic hyperplasia will suffer less lower urinary tract symptoms (LUTS) after conducting self-management intervention than before conducting.

NCT ID: NCT05982444 Active, not recruiting - Clinical trials for Benign Prostatic Hyperplasia

Long Term Follow up of Water Vapor Thermal Therapy (Rezum) for Benign Prostatic Hyperplasia (BPH)

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

in this study the investigators are assessing the effectiveness and morbidity of rezum therapy for benign prostatic hyperplasia by collect data and assess all patient who treated by rezum from 2 to 4 years and report these results.

NCT ID: NCT05785286 Active, not recruiting - Clinical trials for Benign Prostatic Hyperplasia (BPH)

To Linguistically and Psychometrically Validate the Hong Kong Chinese Version of the BPH 3-item Questionnaire

Start date: February 27, 2023
Phase:
Study type: Observational

This study is to linguistically and psychometrically validate the translated and culturally adapted Hong Kong Chinese version of the BPH 3-item questionnaire.

NCT ID: NCT05494567 Active, not recruiting - Overactive Bladder Clinical Trials

Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB

Start date: November 8, 2021
Phase: Phase 4
Study type: Interventional

The investigators will compare the efficacy and safety of tadalafil/solifenacin combination therapy versus tamsulosin/solifenacin combination therapy for the treatment of BPH/OAB in a randomized controlled trial (RCT).

NCT ID: NCT05415748 Active, not recruiting - Clinical trials for Benign Prostatic Hyperplasia

Deprescribing Tamsulosin in Older Men

PERSONAL
Start date: September 18, 2021
Phase: Phase 4
Study type: Interventional

This is a pilot 12-week randomized, placebo-controlled N-of-1 deprescribing trial among older men receiving chronic tamsulosin therapy for lower urinary tract symptoms attributed to benign prostatic hyperplasia.

NCT ID: NCT05395299 Active, not recruiting - Clinical trials for Prostatic Hyperplasia, Benign

Prostatic Arterial Embolization With SQUID (Ethylene Vinyl Alcohol Copolymer )

SQUID
Start date: November 22, 2022
Phase: N/A
Study type: Interventional

The aim of this pilot study is to analyze the feasibility of prostatic embolization for the treatment of symptomatic benign prostatic hypertrophy with a non adhesive liquid embolic agent (Squid)

NCT ID: NCT05186740 Active, not recruiting - Clinical trials for Benign Prostatic Hyperplasia With Symptomatic Lower Urinary Tract Symptoms

ProVee Urethral Expander System IDE Study (ProVIDE)

ProVIDE
Start date: June 9, 2022
Phase: N/A
Study type: Interventional

A study to evaluate the safety, performance, and effectiveness of the ProVee Urethral Expander System (Investigational Device) when used in subjects with symptomatic urinary obstruction related to benign prostatic hyperplasia (BPH).

NCT ID: NCT04987138 Active, not recruiting - Clinical trials for Lower Urinary Tract Symptoms (LUTS)

Safety and Effectiveness Study of the Zenflow Spring System

BREEZE
Start date: September 30, 2021
Phase: N/A
Study type: Interventional

Evaluate the safety and effectiveness of the Zenflow Spring System in relieving LUTS associated with BPH.

NCT ID: NCT04761224 Active, not recruiting - Clinical trials for Prostatic Hypertrophy

Impact of Intraoperative Instillation of Normothermal Saline on the Prevention of Intraoperative Hypothermia and Perioperative Morbidity of Prostatic Enucleation With Holmium Laser

THERMHOLEP
Start date: April 1, 2021
Phase: N/A
Study type: Interventional

For the treatment of benign prostatic hyperplasia (BPH), 2 types of endoscopic surgery are currently performed: transurethral prostate resection (TPR), the reference surgery, and laser prostatic enucleation (LPE). These procedures can be performed under general anesthesia, or local anesthesia, such as spinal anesthesia. The EPL or RTUP procedure requires the instillation of continuous intra-vesical fluids throughout the procedure. These 3L bags are often kept at the ambient temperature of the operating room (around 17°C): the temperature of the instilled solution is therefore much lower than the average body temperature of the patient (37°C). Thus, and by heat exchange, it often results in per and postoperative hypothermia, which is all the more frequent and profound the longer the duration of the operation. In spite of the usual procedures of warming by heating blanket, the prevalence of hypothermia, defined as a body temperature < 36°C, is 53.5% during surgical procedures. This hypothermia is all the more frequent and profound the older the patient is and the longer the duration of anesthesia. Several studies have shown that hypothermia is particularly frequent during abdomino-pelvic surgery, notably due to pathophysiological phenomena induced by anesthetic procedures. Indeed, general anesthesia, or major locoregional anesthesia, disrupts the thermoregulation center upon anesthetic induction, with alteration of peripheral vasoconstriction and tremor capacity, leading to a rapid redistribution of body heat from the center to the periphery. Through exchanges with the environment, this results in a rapid linear decrease in central body temperature that exceeds the metabolic energy produced. However, anesthetic procedures are not the only cause of hypothermic intraoperative phenomena. It has been shown that the decrease in body temperature associated with most genitourinary endoscopic procedures is multifactorial, taking into account the patient's body mass, the volume of fluids instilled, and the type and duration of the operation.